BioCentury | Jul 25, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2019

...inflammation. Harvard University; Emory University Distillery Therapeutics Resolvin D4 (RvD4) Cancer; endocrine/metabolic Bone cancer; metabolic FA complementation group M (FANCM)...
BioCentury | Jun 11, 2019
Distillery Therapeutics

Inhibiting FANCM-TOP3A-RMI1 interaction for osteosarcoma, Lesch-Nyhan syndrome

...with vehicle. Next steps include identifying and testing other inhibitors of the FANCM-RMI1 interaction. TARGET/MARKER/PATHWAY: FA complementation group M (FANCM)...
...Pickett, University of Sydney, Sydney, Australia email: hpickett@cmri.org.au Claire Quang St. Vincent's Institute of Medical Research University of Sydney FA complementation group M (FANCM) Metabolic...
BioCentury | Jul 24, 2018
Distillery Therapeutics

Cancer

...steps could include identifying and testing RAD52 inhibitors in models of FANCM-deficient colorectal cancer. TARGET/MARKER/PATHWAY: FA complementation group M (FANCM)...
...CONTACT: Xiaohua Wu, The Scripps Research Institute, La Jolla, Calif. email: xiaohwu@scripps.edu Claire Quang The Scripps Research Institute FA complementation group M (FANCM) RAD52...
Items per page:
1 - 3 of 3